Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Creative Medical Technology Holdings (CELZ) Change in Accured Expenses (2016 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed Change in Accured Expenses for 15 consecutive years, with -$39920.0 as the latest value for Q1 2025.

  • On a quarterly basis, Change in Accured Expenses changed N/A to -$39920.0 in Q1 2025 year-over-year; TTM through Sep 2025 was -$36920.0, a 1330.67% decrease, with the full-year FY2022 number at $15535.0, down 24.72% from a year prior.
  • Change in Accured Expenses was -$39920.0 for Q1 2025 at Creative Medical Technology Holdings, down from $3000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $35000.0 in Q2 2022 to a low of -$39920.0 in Q1 2025.
  • A 4-year average of -$75.0 and a median of $1907.0 in 2021 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 114.34% in 2022; the steepest drop was 1328.5% in 2022.
  • Creative Medical Technology Holdings' Change in Accured Expenses stood at -$5534.0 in 2021, then tumbled by 171.05% to -$15000.0 in 2022, then skyrocketed by 120.0% to $3000.0 in 2024, then tumbled by 1430.67% to -$39920.0 in 2025.
  • Per Business Quant, the three most recent readings for CELZ's Change in Accured Expenses are -$39920.0 (Q1 2025), $3000.0 (Q3 2024), and -$15000.0 (Q4 2022).